PHAR PHAR
Company Profile ↓Company Overview
PHAR (PHAR) is a publicly traded company listed on with a market capitalization of $7.49B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 22.3% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $376.13M (+26.6% YoY); net profit $2.85M.
- Trailing 12 Months Year-on-year growth — revenue +26.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 22.3%, profit CAGR -40.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 22.30% |
| 1 Year: | 26.56% |
Compounded Profit Growth
| 5 Years: | -40.70% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -12.86% |
| 6 Months: | -38.15% |
| 3 Months: | -33.98% |
| 1 Month: | -26.18% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)33.21 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 22.3% over 5 years.
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 267.0.
- Earnings shrank at -40.7% CAGR over 5 years.
- Trading 49.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | 93.22M | 97.29M | 106.50M | 72.45M | 90.21M |
| Cost of Revenue | - | - | 8.97M | 7.07M | 21.10M | 6.64M | 14.54M |
| Gross Profit | - | - | 84.25M | 90.22M | 85.40M | 65.80M | 75.67M |
| Operating Expenses | - | - | 75.25M | 74.47M | 83.40M | 71.09M | 75.78M |
| Operating Income | - | - | 9.00M | 15.75M | 2.00M | -5.29M | -111.00K |
| EBITDA | - | - | 9.79M | 23.43M | 9.41M | 1.06M | 8.75M |
| Interest Expense | - | - | 4.00K | 7.95M | 1.40M | 2.69M | 2.68M |
| Pretax Income | - | - | 7.08M | 12.76M | 4.80M | -4.75M | 3.04M |
| Tax Provision | - | - | 2.53M | 5.21M | -500.00K | 459.00K | 1.40M |
| Net Income | - | - | 4.69M | 7.55M | 5.30M | -5.21M | 1.64M |
| Diluted EPS | 0.04 | -0.22 | - | - | 0.07 | -0.07 | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 205.62M | 245.32M | 297.20M | 376.13M |
| Cost of Revenue | - | 17.56M | 25.21M | 35.40M | 45.50M |
| Gross Profit | - | 188.06M | 220.10M | 261.80M | 330.63M |
| Operating Expenses | - | 178.20M | 242.39M | 265.47M | 309.75M |
| Operating Income | - | 9.86M | -22.29M | -3.67M | 20.88M |
| EBITDA | - | 33.53M | 9.88M | 16.32M | 34.78M |
| Interest Expense | - | 5.36M | 5.96M | 8.74M | 10.72M |
| Pretax Income | - | 14.99M | -12.01M | -8.49M | 12.85M |
| Tax Provision | - | 1.31M | -1.46M | 3.35M | 10.31M |
| Net Income | - | 13.67M | -10.55M | -11.84M | 2.85M |
| Diluted EPS | - | 0.19 | -0.15 | -0.16 | 0.04 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 425.80M | 462.85M | 399.99M | 499.96M |
| Current Assets | - | 277.50M | 316.34M | 278.44M | 299.47M |
| Cash & Equivalents | - | 207.34M | 61.74M | 54.94M | 145.31M |
| Inventory | - | 42.33M | 56.76M | 55.72M | 64.90M |
| Receivables | - | 20.96M | 35.41M | 41.53M | 41.77M |
| Total Liabilities | - | 221.16M | 244.07M | 178.92M | 222.86M |
| Current Liabilities | - | 59.70M | 77.97M | 73.80M | 115.79M |
| Long Term Debt | - | 131.62M | 136.60M | 78.15M | 92.72M |
| Total Debt | - | 166.69M | 171.54M | 112.31M | 115.78M |
| Total Equity | - | 204.64M | 218.78M | 221.06M | 277.10M |
| Shares Outstanding | - | 656.35M | 671.07M | 680.31M | 701.68M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 22.46M | -17.30M | -1.79M | 54.71M |
| Investing Cash Flow | - | 5.32M | -129.39M | 31.62M | 26.25M |
| Financing Cash Flow | - | -4.98M | -1.04M | -34.41M | 1.50M |
| Capital Expenditure | - | -1.98M | -1.46M | -796.00K | -755.00K |
| Free Cash Flow | - | 20.48M | -18.77M | -2.59M | 53.95M |
| Net Change in Cash | - | 22.80M | -147.73M | -4.59M | 82.45M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 91.5% | 89.7% | 88.1% | 87.9% |
| Operating Margin % | - | 4.8% | -9.1% | -1.2% | 5.6% |
| Net Margin % | - | 6.7% | -4.3% | -4.0% | 0.8% |
| ROE % | - | 6.7% | -4.8% | -5.4% | 1.0% |
| ROCE % | - | 2.7% | -5.8% | -1.1% | 5.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PHAR
Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference
Leiden, the Netherlands, August 4, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR), today announced its participation in the Canaccord Genuity 46th Annual Growth Conference in Boston on August 12-13, 2026. Michael Levitan…
Pharming Group (ENXTAM:PHARM) Could Be 63% Undervalued After Guidance Cut And Half Year Results
Pharming Group guidance cut and half year results draw investor focus Pharming Group (ENXTAM:PHARM) has drawn fresh attention after lowering its 2026 revenue guidance by US$30 million and reporting half year 2026 results that showed reduced…
Pharming Group (PHGUF) (Q2 2026) Earnings Call Highlights: Joenja Surges 40% as Ruconest Faces ...
Pharming Group (PHGUF) navigates a mixed quarter with strong Joenja growth and cost discipline, offset by Ruconest revenue declines and a lowered full-year outlook.
Pharming Group Q2 Earnings Call Highlights
Pharming Group (NASDAQ:PHAR) reported second-quarter revenue of $90.2 million, down 3% from a year earlier, as growth from its Joenja treatment partly offset lower sales of hereditary angioedema therapy RUCONEST. The company reduced its ful…
Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use
For investor audiences and media only Second quarter 2026 total revenues decreased by 3% to US$90.2 million, compared to the second quarter 2025RUCONEST® revenue was US$72.3 million, a 10% decrease compared to the second quarter 2025 and a …
Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30
Leiden, the Netherlands, July 16, 2026: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the second quarter and first half 2026 and prov…
PHAR — Frequently Asked Questions
What is the current share price of PHAR?
As of 2026-08-05 17:25 PDT, PHAR trades at $10.68 on NASDAQ/NYSE. Its 52-week range is $9.82 to $21.18.
What is the market capitalisation of PHAR?
PHAR has a market capitalisation of $7.49B on NASDAQ/NYSE.
What is the P/E ratio of PHAR?
PHAR trades at a trailing price-to-earnings (P/E) ratio of 267.00. Its price-to-book (P/B) ratio is 27.04.
What is the return on equity (ROE) of PHAR?
PHAR has a return on equity (ROE) of 1.03%. Its return on capital employed (ROCE) is 5.44%.
Is PHAR a good stock to buy?
This page provides a data-driven analysis of PHAR, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.